To address complications of pathogenic antibody or life-threatening anaphylactic reactions in protein replacement therapy for patients with hemophilia or other inherited protein deficiencies, we have developed a prophylactic protocol using a murine hemophilia B model. Oral delivery of coagulation factor IX fused with cholera toxin β-subunit (with or without a furin cleavage site; CTB-FFIX or CTB-FIX), expressed in chloroplasts (up to 3.8% soluble protein or 0.4 mg/g leaf tissue), bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies (undetectable or up to 100-fold less than controls). Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous F.IX. Whereas only 20-25% of control animals survived after six to eight F.IX doses, 90-93% of F.IX-fed mice survived 12 injections without signs of allergy or anaphylaxis. Immunostaining confirmed delivery of F.IX to Peyer's patches in the ileum. Within 2-5 h, feeding of CTB-FFIX additionally resulted in systemic delivery of F.IX antigen. This high-responder strain of hemophilia B mice represents a new animal model to study anaphylactic reactions. The protocol was effective over a range of oral antigen doses (equivalent to 5-80 μg recombinant F.IX/kg), and controlled inhibitor formation and anaphylaxis long-term, up to 7 months (∼40% life span of this mouse strain). Oral antigen administration caused a deviant immune response that suppressed formation of IgE and inhibitory antibodies. This cost-effective and efficient approach of antigen delivery to the gut should be applicable to several genetic diseases that are prone to pathogenic antibody responses during treatment.
allergy | chloroplast | genetic disorders | oral tolerance | plant-made therapeutics C urrent treatment of the X-linked bleeding disorder hemophilia is based on intravenous (i.v.) infusion of recombinant or plasmaderived coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) concentrate. In a subset of patients, humoral immune responses to the functional protein develop and pose a serious complication for factor replacement therapy. In hemophilia A, formation of inhibitory antibodies (inhibitors) directed against factor VIII (F.VIII), a helper-T-cell-dependent response, occurs in 20-30% of patients (1) . There is much progress in the risk assessment of inhibitor formation in patients early in therapy, using a combination of genotyping (e.g., determination of the underlying F.VIII mutation and polymorphisms in the promoters of the cytokine genes IL-10 and TNFα), family history of inhibitor formation, ethnicity, and intensity of early treatment (2) . Inhibitors increase the risk for bleeding-related morbidity and mortality. High-titer inhibitors (>5 Bethesda units, BU/mL) prevent treatment with clotting factor product. Bypass reagents, such as activated factor VII, are expensive and pose thrombotic risks. Inhibitors can be eliminated by immune tolerance induction (ITI) protocols, which are based on frequent high-dose infusions of factor for months to several years, and often require amounts of products exceeding $1,000,000.
The overall incidence of inhibitors is considerably lower in hemophilia B (1.5-3%). However, 9-23% of patients with severe disease (<1% coagulation activity) form inhibitors, which are typically high-titer and are almost exclusively confined to subjects with gene deletions or early stop codons (3) . ITI protocols are less effective for treatment of inhibitors to factor IX (F.IX) and sometimes have to be interrupted because of development of nephrotic syndrome. Importantly, studies found that up to 50% of patients with F.IX inhibitors may experience potentially life-threatening anaphylactic reactions to F.IX which also preclude the subject from home treatment and severely hinder ITI protocols (3) . These acute severe and systemic type I hypersensitive allergic reactions, often attributed to IgE formation, have been reported for treatment of hemophilia A and B, lysosomal storage disorders, and others (4) (5) (6) (7) (8) (9) . No prophylactic protocols are currently available for prevention of these pathogenic antibody responses.
Oral delivery of coagulation factors has long been discussed as a potential approach to induce tolerance in hemophilia (10) . However, realization has been elusive, likely because of inefficient delivery of the antigen to the gut-associated lymphoid tissue (GALT). Therefore, we sought to develop an alternative approach, using transplastomic technology as a means of efficient and potentially tolerogenic oral delivery of F.IX. This technology for robust expression and bioencapsulation of therapeutic proteins is based on transformation of plant cells by particle bombardment of plasmid DNA followed by homologous recombination with chloroplast genomes, selection, and regeneration of plants (11, 12) . Transplastomic plants lack gene silencing, regardless of accumulating >100-fold higher transcripts than in nuclear transgenic plants and accumulation of foreign proteins at levels >70% of total leaf protein (13) (14) (15) (16) . Consequently, we and others have been able to produce high levels of several biopharmaceutical proteins and vaccine antigens via the chloroplast system (11, 17) . Foreign proteins expressed in plant chloroplasts can be efficiently delivered to the immune or circulatory system upon oral delivery when they are fused with the transmucosal carrier cholera toxin B subunit (CTB) (14, 18, 19) .
Although the prokaryotic nature of the chloroplast may not perform all of the posttranslational modifications required to produce biologically active F.IX, we reasoned that optimal delivery of the polypeptide to the GALT via bioencapsulation by the plant cell would result in tolerogenic antigen presentation that modulates immune response upon i.v. administration of functional F.IX protein. Results demonstrate that repeated oral delivery of chloroplastderived F.IX suppressed inhibitor development and prevented life-threatening anaphylactic reactions to F.IX replacement therapy in a murine model of hemophilia B.
Results
Construction of Chloroplast Transformation Vector. Both chloroplast vectors pLD CTB-FIX and pLD CTB-FFIX (Fig. 1A ) used in this study are based on the universal chloroplast vector pLD-Ctv that targets the expression cassette into the spacer region between the trnI and trnA genes of the chloroplast genome for integration via homologous recombination (20) . In the CTB-FIX construct, a glycineproline-glycine-proline (GPGP) hinge was created between the fusion elements to prevent steric hindrance, whereas in the CTB-FFIX construct, along with the GPGP hinge, a furin cleavage site was also introduced. The CTB-FIX and CTB-FFIX fusion genes were regulated by the psbA promoter and 5′ untranslated region (UTR) to achieve hyperexpression, as demonstrated previously for several other transgenes (21) . The psbA 3′ UTR placed at the 3′ end of the fusion gene imparted transcript stability. The aadA gene driven by the tobacco plastid ribosomal operon promoter (Prrn) and the GGAG ribosome binding site conferring spectinomycin resistance were used for selection.
Regeneration of Transplastomic Plants and Evaluation of Transgene
Integration by Southern Blot Analysis. Transplastomic tobacco plants were produced as described earlier (12, 22) . Chloroplast transgenic lines were examined by Southern blots to confirm sitespecific transgene integration and to determine homoplasmy or heteroplasmy. Digestion of total plant DNA from untransformed plants (WT) with HindIII generated a 7.67-kbp fragment when hybridized with the 32 P-labeled trnI-trnA flanking sequence probe, indicating no integration of foreign DNA ( Fig. 1 B and C) . All CTB-FIX transplastomic lines showed both 10.88-kb and 7.67-kb fragments, indicating heteroplasmy, whereas all CTB-FFIX transgenic lines showed only the 10.89-kb fragment, indicating homoplasmy. Southern blots confirmed site-specific integration of the transgenes into the spacer region between the trnI and trnA genes ( Fig. 1 B and C) . Homoplasmy in CTB-FIX transgenic lines was not achieved even after additional rounds of selection. This may be due to toxicity created by improperly folded F.IX due to steric hindrance in the absence of a furin cleavage site (GPGP alone was inadequate to prevent steric hindrance). Transplastomic lines with roots were transferred to jiffy pellets and kept under high humidity initially for 2 weeks in a growth chamber before plants were moved to the greenhouse.
CTB-FIX and CTB-FFIX Expression and Pentamer Assembly in Transgenic
Tobacco. Immunoblots probed with CTB antibody showed the presence of an ∼58-kDa fusion protein in both CTB-FIX and CTB-FFIX transplastomic lines. A similar banding pattern was observed by immunodetection with FIX antibody (Fig. 1 D and E) . Pentamer formation was observed in the native PAGE using CTB primary antibody (Fig. 1F) . Quantitation of the fusion protein was carried out by densitometry on Western blots of plant samples using known amounts of purified CTB. The expression levels varied significantly depending on the developmental stages and time of leaf harvest ( Fig. 2 A-C) . Young (top five), mature (fully grown), and old (bottom three) leaves in transplastomic plants were investigated. Fig. 2 A-C show that transplastomic lines have higher F.IX expression in mature leaves. Younger leaf cells contain fewer chloroplasts and the psbA promoter is developmentally regulated; therefore, expression levels were less than in mature leaves. Older senescent leaves had lower accumulation of F.IX, probably due to higher proteolytic activity. Likewise, F.IX expression was higher at 6 PM than at 10 AM because the psbA promoter and 5′ untranslated regions located upstream of the FIX gene cassette are known to enhance translation in the light (15, 16, 23) . Transplastomic lines of CTB-FIX and CTB-FFIX had expression levels of up to 0.19% and 3.8% (0.4 mg/g of leaf tissue) fusion protein, respectively, in the total soluble protein. Introduction of the furin cleavage site clearly stabilized FIX and enhanced its accumulation 20-fold.
Vibrio cholerae secretes an 86-kDa toxin that is made up of two subunits, an α-and a β-subunit (CTB), that contains a binding site for the plasma membrane receptor of the intestinal epithelial cells (GM1) (24, 25) . GM1-ganglioside has been shown to be the receptor for CTB protein in vivo (24) , and a pentameric structure is required for binding to GM1 receptor (25) . As illustrated in Fig. 2D , GM1 ELISA confirms that CTB-FIX and CTB-FFIX fusion proteins assembled properly to form pentameric structures within chloroplasts, which are essential for GM1-ganglioside receptor binding. This assay along with native PAGE confirmed the correct folding and disulfide-bond formation of CTB pentamers within transgenic chloroplasts.
Oral Delivery of F.IX Transplastomic Leaves Suppresses Inhibitor
Formation and Fatal Anaphylaxis in Hemophilia B Mice. Hemophilia B mice with targeted F9 gene deletion on C3H/HeJ genetic background form robust immune responses to human F.IX (hF.IX) upon protein or gene therapy (26) . Therefore, three experimental groups received oral gavage of frozen powdered leaves (250 mg/ dose) twice per week for 2 months, using leaves from untransformed (WT), CTB-FIX, or CTB-FFIX transplastomic plants (repre- senting the equivalent of 0, 0.14, and 2 μg of recombinant hF.IX·dose −1 ·mouse −1 , respectively). Dosage of CTB-FIX and CTB-FFIX for each batch of ground leaf powder was determined before each gavage and uniform doses were delivered. After 1 month, a therapeutic dose of recombinant hF.IX was given i.v. once per week (1 IU per mouse) for 2 months, that is, extending 1 month beyond the feeding protocol (Fig. 3A) . Two more groups received i.v. injections of hF.IX only, without feeding.
In unfed animals (n = 11), severe allergic reactions were observed starting with the fourth i.v. injection of hF.IX, at which time fatal anaphylactic reactions started to occur, and continued subsequently with an incidence of 17-33% (Fig. 3B) . Similarly, WT-fed mice showed severe allergic reactions immediately following the fourth (2 of 10 mice) and fifth injections (3 of 10 mice), including hunched position, piloerection, slowing of movement, tachypnea, and bronchospasms. During subsequent injections, ∼50% of the mice had such reactions. Moreover, starting from the sixth injection, 31-40% of animals died within 30 min to several hours after i.v. injection of hF.IX, apparently from respiratory arrest (Fig. 3C ). We were able to collect blood samples from five remaining mice immediately after the eighth i.v. injection, within 2 h after which three additional mice died. In any case, 75-80% of mice treated with hF.IX were lost within six to eight weekly injections ( Fig. 3 B and C) , unless antianaphylactic drugs were given (see below).
In contrast, 90% of CTB-FIX-and 93% of CTB-FFIX-fed mice (n ≥ 14 per cohort) survived the initial 2-month period of eight weekly hF.IX injections and even subsequent injections (total of 12 exposures; Fig. 3C ). In none of these mice did we observe signs of allergic or anaphylactic reactions. Bethesda assays showed nearly complete to complete suppression of inhibitor formation in mice fed with CTB-FIX (1 ± 0.5 BU/mL) or CTB-FFIX (0.7 ± 0.3 BU/ mL) as compared with background inhibitor titers in naïve hemophilia B mice (no feeding, no treatment; 0.5 ± 0.3 BU/mL). Surviving WT-fed and unfed mice had significantly higher inhibitor titers, which were similar for these groups and ranged from 2 to 8 BU/mL and 2.5 to 10 BU/mL, respectively (Fig. 3D) .
We suspected that these data underrepresented protein therapyinduced inhibitor titers in the control groups, because those mice with fatal hypersensitive responses likely had stronger immune responses. To address these points, we first analyzed plasma obtained from unfed hemophilia B mice after only four weekly hF.IX injections. These had substantially higher inhibitor titers of 8-90 BU/mL (Fig. 3D) , and the three of seven mice with the highest titers died after the fifth hF.IX administration (arrows in Fig. 3D ). Second, five mice that had survived a fifth injection received the sixth dose of hF.IX under coverage with antihistamine and anti-platelet activating factor (PAF). In this case, all five mice survived without allergic or anaphylactic response (Fig. 3B) . Inhibitor titers were measured in four of these mice and were very high (29-87 BU/mL; Fig. 3D ).
Oral Administration of Bioencapsulated hF.IX Can Control Inhibitor
Formation Long Term. One month after the last hF.IX injection, one additional i.v. administration of hF.IX was performed in nine CTB-FFIX-fed mice (i.e., 2 months after the last feeding; Fig. 3E ). This resulted in an increase of inhibitors to an average of 4 BU/mL (Fig. 3E) . Subsequently, treatment was resumed for 1 month (i.e., weekly i.v. infusions of hF.IX) while also continuing the feeding (three oral gavages per week). At the end of this regimen, inhibitor titers had declined to baseline (Fig. 3E) , indicating that the protocol can be used to control inhibitor formation long-term. Again, no allergic or anaphylactic responses were observed.
Oral Administration of Bioencapsulated hF.IX Suppresses Formation of IgE and Inhibitors via an Immune Deviation Mechanism. Analysis of hF.IX-specific Ig formation showed that CTB-FIX/CTB-FFIXfed mice (and surviving WT-fed mice) had average circulating IgG1 titers which were significantly lower when compared with control mice that were kept alive with antihistamine/anti-PAF (Fig. 4A) . Whereas IgG1 titers in control mice correlated well with inhibitor titers, there was no correlation in CTB-FIX/CTB-FFIX-fed mice, which therefore had formed noninhibitory antibodies (Fig. 4C) . The noninhibitory antibodies in CTB-FFIX-fed mice that formed upon protein therapy, in contrast to the inhibitors that developed in WTfed mice, did not cause enhanced clearance of i.v. infused hF.IX from the circulation (Fig. 4F) . The noninhibitory antibodies also did not prevent correction of coagulation activity (as determined by activated partial thromboplastin time), which was raised from <1% at baseline to 16-25% of normal at 30 min after i.v. injection of 1 IU hF.IX (n = 5). Naïve mice treated in parallel showed comparable results (16-18% of normal at 30 min after treatment).
Importantly, three of seven control mice that had received four injections of hF.IX had detectable IgE titers, and titers of >50 ng/mL were predictive of subsequent fatal responses (Fig. 4B, arrows) . Higher-titer IgE was found in four of five analyzed mice that had received a sixth injection concomitant with antihistamine/anti-PAF (Fig. 4B) . These control mice showed a correlation between high-titer IgG1 (>40 μg/mL) and IgE formation, indicating that repeated i.v. administrations boosted Th2-driven antibody formation, resulting in activation of additional B cells with class switching to IgE (Fig. 4D) . This correlation was not seen in CTB-FFIX-fed mice, some of which developed IgG1 titers that would have been predicted to be associated with IgE (Fig. 4D) . CTB-FIX/FFIX-fed mice had IgE titers of <40 ng/mL (the background of our assay) and no anaphylactic responses. Allergic reactions in rodents, although not previously identified in hemophilic mice, in general are caused by histamine and PAF release for IgE-dependent reactions, whereas an alternative, IgG-dependent pathway has also been described, which, however, does not involve histamine (27) . To address this point, additional control mice received hF.IX administration under coverage with anti-PAF alone (i.e., without antihistamine), resulting in fatal anaphylaxis in all three animals tested, thereby further supporting an IgE-dependent mechanism in the hemophilia B mice.
None of the WT-fed or unfed mice formed IgG2a against hF.IX, thereby ruling out an IgG2a/complement-dependent mechanism of anaphylactoid reactions. Whereas IgG2a formation was highly variable and inconsistent in CTB-FIX/CTB-FFIX-fed mice, tolerized mice consistently had circulating low titers of TGF-β-dependent antibodies IgG2b and IgA, the hallmark subclass of a mucosal antibody response (Fig. 4E) .
CTB-FFIX Material Delivers hF.IX Antigen to the GALT and into the
Circulation. Feeding by CTB-FIX or CTB-FFIX material by itself did not cause a detectable systemic antibody response against hF. IX. Immunostaining demonstrated that feeding resulted in delivery of hF.IX antigen to the ileum, predominantly to the interphase between microfold (M) cells and CD11c + dendritic cells in Peyer's patches (Fig. 5 A and B) . Within 2-5 h, feeding of CTB-FFIX material also resulted in systemic delivery of hF.IX antigen to the liver and into plasma (Fig. 5 D and F) . In the case of unfed mice, no signal was detected in ileum (Fig. 5C) or liver (Fig. 5E ).
Discussion
Oral tolerance for hemophilia has been discussed for the past decade but has not been realized, in part because of challenges in effective delivery of coagulation factor antigen to the gut. A recent study concluded that the amount of coagulation factor required for feeding would be cost-prohibitive even for mouse experiments and therefore was not pursued (28) . Here we used an alternative technology that allows for efficient production, bioencapsulation, and delivery of antigens to the GALT (14, 18, 29, 30 ).
Human F.IX was produced at a high level in plant chloroplasts as a fusion protein. The CTB fusion ensures stability of the transgenic protein in the chloroplast, and the nontoxic B subunit exhibits specific and high-affinity binding to the oligosaccharide domain of ganglioside GM1 (a lipid-based membrane receptor), thereby tethering the protein to the plasma membrane of host cells of the intestinal epithelium upon release from the plant cells in the ileum (18, 31) .
Priming with CTB-FIX via an oral route reduced Th2-dependent antibody responses against i.v. hF.IX, and in particular protected from IgE formation, thereby eliminating allergic and anaphylactic reactions. Moreover, reintroduction of the antigen via the oral route successfully controlled inhibitor formation long-term without a need for immune-suppressive drugs. Interestingly, plant materials expressing 20-fold different antigen levels were effective, which should facilitate clinical translation. The furin cleavage site, which directs release and exocytosis of the fused protein from gut epithelia, was not required for treatment (but improved expression and accumulation of FIX in plant cells). These results imply that introduction of F.IX to the GALT was key to successful immune-modulatory therapy. It is generally thought that persistence of the antigen is required to maintain tolerance. Thus, it is likely that oral delivery has to be repeated beyond the induction phase, perhaps every 2 months, to maintain hyporesponsiveness longterm. It should be possible to optimize the protocol so that less intensive repeated oral dosing is effective for maintenance.
Repeated injections of hF.IX caused fatal reactions in most control animals, so that only mice survived that were either low responders or, possibly, spontaneously controlled the pathogenic antibody response. The magnitude of the antibody response was unmasked by pharmaceutical blockage of histamine release, thereby allowing animals to survive despite high production of IgE against hF.IX. Tests to detect IgE responses in patients with hemophilia have been developed, such as RAST (radioallergosorbent test) (9) . However, there are no protocols for preventing or suppressing IgE formation, nor has there been an animal model that mimics this aspect of hemophilia pathophysiology. Similar to observations in humans, the strain of mice we iden- tified as prone to anaphylactic reactions has an F9 gene deletion (8) . A lack of prior reports on anaphylactic reactions to coagulation factors may be because protein replacement therapy has been largely studied using F.VIII infusions to hemophilia A mice (which, similar to human treatment, is less likely to cause anaphylaxis). Hemophilia B mice were primarily used for gene therapy studies and/or bred on C57BL/6 background (which shows weaker immune responses to F.IX) (32) .
Symptoms in the hemophilia B mice were similar to IgE-mediated severe anaphylactic reactions observed in the treatment of other genetic diseases, including hemophilia A and the lysosomal storage disorders Pompe disease (acid α-glucosidase deficiency) and Fabry disease (α-galactosidase A deficiency) (5) (6) (7) 33) . In treatment of hemophilia B, strong evidence has been provided for IgE-mediated anaphylactic reactions (9, 34) . However, IgG/complement-mediated mechanisms have also been proposed (4), and IgE formation may therefore not be the only source of anaphylactoid reactions in humans with hemophilia.
Protection of hemophilia B mice from inhibitor and IgE responses involved a deviant immune response characterized by suppression of IgE and of high-titer IgG1, formation of nonneutralizing antibodies instead of inhibitors, and production of additional Ig subclasses (albeit at very lower titers). Interestingly, the presence of nonneutralizing antibodies has also been described in clinical ITI protocols (4). IL-4 production by CD4 + T cells, that is, by Th2 cells, promotes both IgG1 and IgE class switching. However, it has been proposed that gutassociated regulatory T cells expressing IL-10 may suppress IgE formation (35) . Our findings on induction of IgG2b and IgA suggest a role for TGF-β, possibly derived from Th3 cells, in modulation of F.IX-specific B-cell activation.
Notably, the response to the allo-or autoantigen introduced to the GALT by oral administration of chloroplast transgenic plant material modulates responses to the antigen in other tissues, which we exploited to develop oral tolerance protocols (14) . The oral delivery protocol described here offers solutions for complications encountered with alternative strategies such as gene transfer or transient immune-suppressive regimens (36) . Genetic manipulation poses risks of immunotoxicities and insertional mutagenesis; immunesuppressive drugs have side effects and increase the risk for opportunistic infections, and long-term consequences of use in pediatric patients are unclear. Administration of peptides to mucosal surfaces has also been described, which, however, is complicated in an outbred population because it requires knowledge of CD4 + T-cell epitopes (37) .
The chloroplast system overcomes major limitations of protein production by elimination of highly expensive fermentation and purification systems, cold storage, transportation, and sterile injections. Genetically modified chloroplast genomes of most crops are maternally inherited, and the absence of any reproductive structures offers efficient foreign gene containment (38, 39) and therefore facilitates their safe production in the field (23) . Plant cells provide bioencapsulation and protect therapeutic proteins from degradation in the stomach from acids and enzymes (30) . Plants also reduce concerns about pathogen contamination as may be the case for production of proteins in transgenic animals. Whereas these initial studies were carried out in nonfood tobacco plants, the lettuce chloroplast transformation system has been well-developed for expression of human therapeutic proteins (14, 16) .
With the recent development of novel protein replacement therapies for genetic diseases, more reports are coming forward on immunotoxicities caused by protein infusion. Oral administration of transplastomic plant tissue provides an avenue for prevention and control of pathogenic antibody responses and anaphylactic reactions to systemically delivered therapeutic proteins.
Materials and Methods
Vector Construction. Two CTB fusion constructs were made with human factor IX (FIX). To prevent steric hindrance, a glycine-proline-glycine-proline (GPGP) hinge was introduced between the CTB and FIX in one of the constructs. A furin cleavage site was also introduced along with the GPGP hinge in the second construct. The cDNA sequence encoding F.IX was obtained from the American Type Culture Collection and amplified using sequence-specific restriction-site flanking primers and a cDNA clone of human factor IX as template. The PCR product was then cloned into the pCR BluntII Topo vector (Invitrogen) and the sequence was verified. Following SmaI/XbaI digestion, the FIX gene was ligated into the pLD Ctv 5CP chloroplast transformation vector (14) to create pLD-CTB FIX (only a GPGP hinge between CTB and FIX) and pLD-CTB FFIX (with a GPGP hinge and furin cleavage site between CTB and FIX) vectors.
Regeneration of Transplastomic Plants and Confirmation of Transgene
Integration by Southern Blot. Transplastomic plants using chloroplast expression vectors pLD CTB-FIX and pLD CTB-FFIX were regenerated as described elsewhere (12, 22) . Total plant DNA (1-2 μg) isolated from leaves using a Qiagen DNeasy Plant Mini Kit was digested with HindIII, and Southern blot analysis was carried out to confirm integration and determine homoplasmy as described previously (22) . Southern blots were hybridized with a [ 32 P]α[dCTP]-labeled chloroplast flanking sequence probe (0.81 kb) containing the trnI-trnA genes. The transplastomic plants with roots were transferred to a greenhouse as described previously (12) .
Immunoblot Analysis. Young, mature, and old leaves from transformed plants grown in a greenhouse were collected at 10 AM, 2 PM, and 6 PM. Chloroplastderived CTB-FIX and CTB-FFIX proteins were extracted from 100 mg of powdered leaf material as described earlier (12, 22) . Equal amounts of total protein along with known amounts of purified bacterial CTB (Sigma) were separated by SDS/PAGE and transferred to a nitrocellulose membrane by electroblotting. Immunoblotting with rabbit anti-CTB primary polyclonal antibody (1:3,000; Sigma) and horseradish peroxidase (HRP) -conjugated donkey anti-rabbit secondary antibody (1:5,000; Southernbiotech) was used for densitometric analysis (12, 16, 19) . A SuperSignal West Pico HRP Substrate Kit (Pierce) was employed for detection of chemiluminescence signal by exposure to film. Fusion protein was also detected using goat anti-human factor IX (1:3,000; Enzyme Research) antibody followed by donkey anti-goat IgG-HRPconjugated secondary antibody (1:5,000; Santa Cruz Biotechnology). Native PAGE was also carried out and fusion protein was detected as described above. GM1 receptor binding assays were performed as described previously (40) . as published (26, 41) . Animals were housed under special pathogen-free conditions at the University of Florida and treated under Institutional Animal Care and Use Committee-approved protocols. The leaf material for oral delivery was ground in liquid nitrogen with mortar and pestle and stored at −80°C until the day of administration. Oral doses (250 mg each) of either untransformed or transgenic leaf material were resuspended in 200 μL of sterile PBS and homogenized on ice for 5 min with an OMNI International (GLH-2596) probe. The plant cell suspension was stored on ice until oral delivery via oral gavage using a tuberculin syringe and a 20-G bulb-tipped gastric gavage needle (Popper and Sons) while maintaining the animals under light anesthesia. Recombinant hF.IX (Benefix) was injected into the tail vein at 1 IU (4-5 μg hF.IX) per mouse. Plasma samples were collected by tail bleed into citrate buffer as described (26) . For clearance studies, mice were bled from the retro-orbital plexus using heparinized microcapillary tubes. To block anaphylactic reactions, 150 μg antihistamine (triprolidine; Sigma) and 50 μg antiplatelet-activating factor (PAF) CV-3988 were coinjected i.v. (in 100 μL PBS) 5 min before administration of hF.IX.
Antigen and Antibody Measurements. Plasma levels of hF.IX antigen were measured by ELISA and inhibitory antibody titers were determined by Bethesda assay as published (26) . One Bethesda unit (BU) represents the degree of inhibition that results in 50% residual coagulation activity. Immunocapture assays to determine titers of hF.IX-specific Ig subclasses were as described using IgA, IgE, IgG1, IgG2a, and IgG2b standards from Sigma. To measure IgE titers, IgG was removed from plasma samples using protein G agarose (Pierce; Thermo Scientific) before addition to microtiter plates coated with hF.IX protein. Statistical comparisons between experimental groups were assessed with unpaired Student's t test. Differences were considered significant and reported with *P < 0.05, **P < 0.01, ***P < 0.001, and so on.
Immunohistochemistry. Mice were fed with CTB-FFIX material (250 mg) twice per day for 2 days and killed 5 h after the last gavage, and tissue was collected as described (26) . Cryosections (10-μm thick) were fixed in acetone for 5 min, air-dried, and then rehydrated in PBS. Sections were blocked with 2% donkey serum in PBS for 30 min. Goat α-hF.IX (1:400; Affinity Biologicals), rat α-F4/80 (clone: C1:A3-1; 1:200; AbD Serotec), and biotinylated-α-CD11c (1:200; BD Biosciences) were applied in 2% donkey serum for 30 min. After a washing, tissue sections were incubated with secondary antibody Alex Fluor-488 donkey α-rat IgG, Alex Fluor-568 donkey (or FITC) α-goat IgG, and streptavidin-Alexa Fluor-350 (1:100 dilution; Invitrogen). Some sections were incubated with FITC-labeled Ulex europaeus agglutinin (UEA-1; Vector Labs; 10 μg/mL) for 10 min before being washed and mounted with or without DAPI. Images were captured using a Nikon Eclipse 80i fluorescence microscope and Retiga 2000R digital camera (QImaging) and analyzed with Nikon Elements software.
